These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37344934)

  • 21. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S168-S175. PubMed ID: 28838198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
    Thompson KM; Kalkowska DA; Badizadegan K
    Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):266-272. PubMed ID: 32144841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
    Thompson KM; Kalkowska DA
    Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
    [No Abstract]   [Full Text] [Related]  

  • 25. Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.
    Kalkowska DA; Wiesen E; Wassilak SGF; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
    Risk Anal; 2024 Feb; 44(2):379-389. PubMed ID: 37344376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020.
    Alleman MM; Jorba J; Greene SA; Diop OM; Iber J; Tallis G; Goel A; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(16):489-495. PubMed ID: 32324719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.
    Alleman MM; Jorba J; Henderson E; Diop OM; Shaukat S; Traoré MA; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1691-1699. PubMed ID: 34882653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
    Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
    Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
    Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling the dynamics of oral poliovirus vaccine cessation.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An economic analysis of poliovirus risk management policy options for 2013-2052.
    Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
    Modlin JF; Bandyopadhyay AS; Sutter R
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S398-S404. PubMed ID: 34590135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outbreak management strategies for cocirculation of multiple poliovirus types.
    Kalkowska DA; Badizadegan K; Thompson KM
    Vaccine; 2023 Jun; 41(25):3718-3727. PubMed ID: 37121801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The risk of type 2 oral polio vaccine use in post-cessation outbreak response.
    McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD
    BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.